Answers are grounded in this paper and cite their sources.
Novel therapies such as bortezomib and immunomodulatory agents (IMiDs®) have significantly improved the survival of patients with multiple myeloma (MM) [1]. However, the prognosis remains poor for ...
No takes yet. Share an insight, caveat, or question.
Wolf et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: